Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21155326 | 1.00 | CCR5 (0.30) | CCR5GBA1 | |
| SCHEMBL23773464 | 1.00 | CCR5 (0.30) | CCR5GBA1 | |
| SCHEMBL463582 | 0.87 | — | — | |
| SCHEMBL24070639 | 0.85 | — | — | |
| SCHEMBL20334898 | 0.85 | — | — | |
| SCHEMBL26523757 | 0.85 | — | — | |
| SCHEMBL21155007 | 0.84 | — | — | |
| SCHEMBL21154996 | 0.79 | — | — | |
| SCHEMBL23773121 | 0.79 | — | — | |
| SCHEMBL21155753 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023274258-A1 | HETEROATOM-SUBSTITUTED AROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川大学华西医院 | 2023-01-05 | — | — | WO | disclosed |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210253577-A1 | BIODEFENSE AGENTS | BioVersys AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-10934295-B2 | Antimicrobials and methods of making and using same | BioVersys AG (CH) | 2021-03-02 | — | — | US | disclosed |
| US-20190211018-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | RIB-X PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934295-B2 | Antimicrobials and methods of making and using same | LPO, MPO, OAT | CCR5 4083/4885GBA1 1473/4885 |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | CCR5 2960/4885GBA1 1075/4885 |
| US-20210253577-A1 | BIODEFENSE AGENTS | BPGM, DDT, UNG | CCR5 2507/4885GBA1 223/4885 |
| US-20190211018-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | LPO, MPO, OAT | CCR5 4083/4885GBA1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.